RWD R510-22 Isoflurane Inhalation Anesthetic for Veterinary and Preclinical Research
| Brand | RWD |
|---|---|
| Origin | Shenzhen, China |
| Manufacturer Type | OEM Manufacturer |
| Country of Origin | China |
| Model | R510-22 |
| Price | Upon Request |
Overview
RWD R510-22 Isoflurane is a high-purity, USP-grade inhalation anesthetic formulated specifically for controlled general anesthesia in laboratory animals during surgical, imaging, and physiological research procedures. As a halogenated ether derivative, isoflurane acts via reversible depression of central nervous system synaptic transmission, primarily through potentiation of GABAA receptors and inhibition of excitatory neurotransmission. Its pharmacokinetic profile—characterized by low blood–gas partition coefficient (λb/g ≈ 1.4), rapid pulmonary uptake and elimination, and minimal biotransformation (99.9%), residual solvent limits, and batch-to-batch consistency, ensuring reproducible anesthetic onset (within 60–90 s) and emergence (mean time to spontaneous eye blink: <120 s post-discontinuation) in rodents, rabbits, non-human primates, and other common preclinical species.
Key Features
- USP/EP-compliant isoflurane with certified purity ≥99.9%, verified by gas chromatography (GC) and residual impurity profiling per ICH Q3A(R2)
- Stable vapor pressure (24°C: 238 mmHg) compatible with standard calibrated precision vaporizers (e.g., Ohmeda, Matrx, RWD VAP-2000)
- Non-flammable under normal operating conditions; Class II, Group A2 safety classification per NFPA 56E
- Manufactured under ISO 9001-certified quality management system with full traceability from raw material sourcing to final packaging
- Supplied in tamper-evident, aluminum-sealed glass bottles (100 mL, 250 mL, and 500 mL options) with integrated desiccant cap to prevent moisture ingress and oxidation
- Batch-specific Certificate of Analysis (CoA) provided, including GC chromatograms, water content (Karl Fischer), acidity (titratable HCl), and heavy metal limits (Pb, Cd, As, Hg)
Sample Compatibility & Compliance
RWD R510-22 Isoflurane is validated for use across standard rodent, lagomorph, and non-human primate anesthesia protocols. It exhibits no clinically significant interactions with commonly co-administered agents such as glycopyrrolate, meloxicam, or buprenorphine. The product meets the labeling and documentation requirements of China’s Veterinary Drug Administration (CNDA) and holds Guangdong Province Veterinary Drug Advertising Approval No. Yue Shouyao Guangshen (2025) 44030005. While not intended for human use, its manufacturing process adheres to principles aligned with Good Manufacturing Practice (GMP) for veterinary pharmaceuticals and supports GLP-compliant study execution per OECD Principles of Good Laboratory Practice (GLP) Series No. 1. All batches undergo sterility testing per CPV 2.6.1 and endotoxin quantification (<0.5 EU/mL) using kinetic chromogenic LAL assay.
Software & Data Management
As a pharmaceutical agent rather than an electronic instrument, R510-22 does not incorporate embedded software or digital interfaces. However, its integration into automated anesthesia delivery systems—including RWD’s VAP-2000 Smart Vaporizer and third-party platforms (e.g., Kent Scientific, Harvard Apparatus)—supports digital logging of vaporizer settings, flow rates, and duration of administration via external data acquisition modules compliant with FDA 21 CFR Part 11 (electronic records and signatures). Full audit trails, user access controls, and electronic signature capabilities are maintained at the system level when deployed within regulated preclinical environments.
Applications
- Induction and maintenance of surgical anesthesia in murine models undergoing craniotomy, thoracotomy, or orthopedic implantation
- Functional neuroimaging (fMRI, PET, optical intrinsic signal imaging) requiring stable, motion-free physiological states
- Longitudinal electrophysiological recordings (EEG, LFP, single-unit) where rapid reversibility minimizes post-procedural confounds
- Cardiovascular studies involving echocardiography or pressure-volume loop analysis under hemodynamically stable conditions
- Development and validation of novel inhalational anesthetic delivery devices and closed-loop anesthesia systems
FAQ
Is RWD R510-22 Isoflurane approved for use in GLP-regulated toxicology studies?
Yes—when used in accordance with its CoA, storage conditions (15–25°C, protected from light), and validated vaporizer calibration protocols, it satisfies material qualification requirements for nonclinical safety studies conducted under OECD GLP or US FDA GLP regulations.
What is the recommended storage condition and shelf life?
Store unopened bottles upright at 15–25°C, away from direct sunlight and ignition sources. Shelf life is 36 months from manufacture date when sealed; 12 months after first opening if resealed with original cap and stored under inert gas overlay.
Does this product require special handling or ventilation during use?
Yes—use only in well-ventilated areas or with active scavenging systems meeting ISO 10993-12 and NIOSH Recommended Exposure Limits (REL: 500 ppm TWA). Personnel must wear appropriate PPE including nitrile gloves and respiratory protection when refilling vaporizers.
Can R510-22 be used interchangeably with other commercial isoflurane products?
Yes—its physicochemical identity and pharmacological equivalence to USP isoflurane ensure functional interoperability with all FDA-cleared vaporizers and animal monitoring systems; however, vaporizer calibration must be confirmed per manufacturer specifications prior to first use.
